Sto SE & Co. KGaA (STO3)
XETRA Stock Exchange · Germany · prices in EUR · close of 23 Oct 2026
Key indicators
| Last close | EUR 101.60 |
|---|---|
| 52-week range | 90.80 – 130.60 |
| Return, 1 month / 3 months | +3.5% / +8.0% |
| Return, 1 year / 3 years | −15.0% / −6.5% |
| Trend | Below its 200-day average |
| RSI (14) | 55 |
| Volatility (1 year) | 24.5% |
| Worst drawdown (1 year) | -27.6% |
| Average daily value traded | 0.30M EUR |
| Dividend yield | 3.3% |
Market X-Ray price-based
Five-year price chart navy: price · brown: 200-day average
About the company
Sto SE & Co. KGaA is a German building materials company based in Stühlingen that develops and makes products for facades and interiors. Its range covers exterior wall insulation systems, facade coatings and renders, along with interior paints, plasters and acoustic systems. The company serves architects, contractors, applicators and building owners, and it sells through subsidiaries and distribution partners in many countries, with its home market in Germany and wider Europe.
Sto SE & Co. KGaA trades under the code STO3 on the XETRA Stock Exchange in Germany, with its price quoted in euros (EUR). Our dividend records, which start in 2019, show payments in 8 different calendar years. The Market X-Ray on this page is price-based and compares it with other stocks on the same exchange; it does not measure how healthy the business is.
Summary
Sto SE & Co. KGaA (STO3) trades on the XETRA Stock Exchange in Germany. It last closed at EUR 101.60 on 23 October 2026.
Its price-based Market X-Ray is 56 out of 100 (a fair price profile), ranking 306 of 701 stocks on this exchange. The score describes how the stock has traded: trend, momentum, risk, liquidity and dividends, each ranked against the other stocks on its own exchange. It does not measure how healthy or cheap the business is.
Over the last year the price fell 15.0% and over the last three months it rose 8.0%. Returns are price returns, dividends not included.
Fundamental measures (valuation, growth, financial health) are not shown: we do not yet hold financial statements for this market.
The five lenses in numbers each metric is ranked against the other stocks on XETRA Stock Exchange
| Lens and metric | Value | Score | Reading |
|---|---|---|---|
| Trend | 47 · Weak | Below its long-term averages and far from its highs. | |
| Above 200-day average | -1.2% | ||
| From 52-week high | -22.1% | ||
| Momentum | 49 · Weak | Lagging most stocks on this exchange. | |
| 3-month return | 8.0% | ||
| 6-month return | -4.5% | ||
| 12-month return, skipping the last month | -17.8% | ||
| Stability (higher is calmer) | 71 · Strong | Calmer than most: low volatility and shallow drawdowns. | |
| Volatility, 1 year (lower is calmer) | 24.5% | ||
| Worst drawdown, 1 year (smaller is calmer) | -27.6% | ||
| Liquidity | 59 · Fair | Moderate trading activity. | |
| Average daily value traded | 0.30M EUR | ||
| Zero-volume days | 0.0% | ||
| Income | 57 · Fair | Dividend is typical for this exchange. | |
| Dividend yield | 3.3% | ||
| Years with dividends | 5 |
Strengths
- Stability (higher is calmer): Calmer than most: low volatility and shallow drawdowns.
Weak spots
- Trend: Below its long-term averages and far from its highs.
- Momentum: Lagging most stocks on this exchange.
Returns
| 1 week | −0.6% |
|---|---|
| 1 month | +3.5% |
| 3 months | +8.0% |
| 6 months | −4.5% |
| 1 year | −15.0% |
| 3 years | −6.5% |
| 5 years | −39.9% |
Signals
| 50-day / 200-day average | 99.17 / 102.80 |
|---|---|
| Golden / death cross (60 days) | None |
| New 52-week high | No |
| Bullish RSI divergence | No |
| Average daily range (ATR) | 2.59 |
Technical summary
Recent dividends
| Ex-dividend date | Amount per share |
|---|---|
| 19 Jun 2026 | EUR 3.3100 |
| 19 Jun 2025 | EUR 3.3100 |
| 20 Jun 2024 | EUR 5.0000 |
| 22 Jun 2023 | EUR 5.0000 |
| 23 Jun 2022 | EUR 5.0000 |
| 17 Jun 2021 | EUR 5.0000 |
How to read this report
Every number comes from end-of-day prices and dividends. The Market X-Ray describes how the stock has traded, ranked against the other stocks on XETRA Stock Exchange; it does not measure how healthy or cheap the business is. The fundamental X-Ray (financial health, valuation, growth) needs financial statements, which we hold today for US stocks. See the methodology page. Educational only, not financial advice.